Vitamin E supplementation and the retinopathy of prematurity
| Autor: | Chari Otis, Mari Jo Mathis, David B. Schaffer, Donald J. Goldstein, Thomas R. Boggs, Lois Johnson, Graham E. Quinn |
|---|---|
| Rok vydání: | 1982 |
| Předmět: |
Pediatrics
medicine.medical_specialty medicine.medical_treatment Vitamin e supplementation Legal blindness Disease General Biochemistry Genetics and Molecular Biology History and Philosophy of Science Pregnancy medicine Animals Humans Vitamin E Retinopathy of Prematurity Clinical Trials as Topic Milk Human business.industry General Neuroscience Incidence (epidemiology) Colostrum Infant Newborn Retinopathy of prematurity medicine.disease Clinical trial Milk Cattle Female Infant Food business Infant Premature Follow-Up Studies |
| Zdroj: | Annals of the New York Academy of Sciences. 393 |
| ISSN: | 0077-8923 |
| Popis: | The effect of high-dosage E treatment (Rx) initiated at the stage of 3-plus active disease (target serum E levels, 5-6 mg/dl) was evaluated by a standardized scoring system of visual morbidity at the one to two year eye exam among infants cared for in the University of Pennsylvania Neonatal Complex (1976-1978). The incidence of legal blindness in both eyes or worse was decreased from 71 to 40% in E Rx (n = 10) as compared to non-E Rx (n = 14) infants, and the number of infants with minimal visual morbidity was increased. Pilot studies (1972-76; target serum E level, 1.5 and 3.0 mg/dl) of the prophylactic effect of E Rx from birth on showed a decrease in mean severity of acute stage disease and a decrease in sequelae at one to two years. A strikingly difference in visual morbidity following resolved low-grade ROP was seen when prestudy infants (1968-72) who were fed early iron supplements and given formulas with low E:PUFA ratios were compared to non-E Rx as well as to E Rx 1972-76 infants. Vitamin E seems to exert a beneficial effect at all stages of ROP, perhaps because of its broadly based regulatory role. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text